Evommune, Inc. EVMN
We take great care to ensure that the data presented and summarized in this overview for Evommune, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in EVMN
Top Purchases
Top Sells
About EVMN
Insider Transactions at EVMN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 19
2025
|
Robert Lorne Hopfner Director |
BUY
Open market or private purchase
|
Indirect |
1,000
+19.9%
|
$17,000
$17.35 P/Share
|
|
Dec 09
2025
|
Kyle Carver Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,290
-17.53%
|
$225,930
$17.84 P/Share
|
|
Dec 09
2025
|
Janice Suzann Drew EVP, Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
5,074
-6.96%
|
$86,258
$17.84 P/Share
|
|
Dec 09
2025
|
Gregory S. Moss Chief Business & Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,624
-18.3%
|
$231,608
$17.84 P/Share
|
|
Dec 09
2025
|
Jeegar Pravinkumar Patel Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,513
-13.16%
|
$127,721
$17.84 P/Share
|
|
Dec 09
2025
|
Luis C. Pena President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
28,138
-4.12%
|
$478,346
$17.84 P/Share
|
|
Dec 09
2025
|
Eugene Bauer Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,478
-0.54%
|
$25,126
$17.84 P/Share
|
|
Nov 07
2025
|
Pivotal Bio Venture Partners Fund I, L.P. Director |
BUY
Conversion of derivative security
|
Indirect |
3,367,975
+50.0%
|
-
|
|
Nov 07
2025
|
7 Cooperative Ua Lsp |
BUY
Open market or private purchase
|
Direct |
1,562,500
+24.07%
|
$25,000,000
$16.0 P/Share
|
|
Nov 07
2025
|
7 Cooperative Ua Lsp |
BUY
Conversion of derivative security
|
Direct |
3,367,133
+50.0%
|
-
|
|
Nov 07
2025
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,250,000
+20.39%
|
$20,000,000
$16.0 P/Share
|
|
Nov 07
2025
|
Ra Capital Management, L.P. |
BUY
Conversion of derivative security
|
Indirect |
2,208,770
+50.0%
|
-
|
|
Nov 07
2025
|
Eugene Bauer Chief Medical Officer |
BUY
Conversion of derivative security
|
Direct |
25,812
+8.66%
|
-
|
|
Nov 07
2025
|
Robert Lorne Hopfner Director |
BUY
Conversion of derivative security
|
Indirect |
3,371,001
+50.0%
|
-
|
|
Nov 07
2025
|
Gregory S. Moss Chief Business & Legal Officer |
BUY
Conversion of derivative security
|
Indirect |
3,175
+50.0%
|
-
|
|
Nov 07
2025
|
Jeegar Pravinkumar Patel Chief Scientific Officer |
BUY
Conversion of derivative security
|
Direct |
3,175
+5.27%
|
-
|
|
Nov 07
2025
|
Luis C. Pena President & CEO |
BUY
Conversion of derivative security
|
Direct |
24,225
+3.43%
|
-
|
|
Nov 07
2025
|
Weegen Felice Isabel Verduyn Van |
BUY
Open market or private purchase
|
Indirect |
1,562,500
+24.07%
|
$25,000,000
$16.0 P/Share
|
|
Nov 07
2025
|
Weegen Felice Isabel Verduyn Van |
BUY
Conversion of derivative security
|
Indirect |
3,367,133
+50.0%
|
-
|
|
Nov 07
2025
|
Kyle Carver Chief Financial Officer |
BUY
Conversion of derivative security
|
Direct |
3,175
+4.02%
|
-
|
Last 12 Months Summary
Buy / Acquisition
20.1M
Shares
From
16
Insiders
| Conversion of derivative security | 15.7M shares |
|---|---|
| Open market or private purchase | 4.38M shares |
Sell / Disposition
69.1K
Shares
From
6
Insiders
| Payment of exercise price or tax liability | 69.1K shares |
|---|